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Abstract: Neorogioltriol is a tricyclic brominated diterpenoid isolated from the organic 
extract of the red algae Laurencia glandulifera. In the present study, the anti-inflammatory 
effects of neorogioltriol were evaluated both in vivo using carrageenan-induced paw edema 
and in vitro on lipopolysaccharide (LPS)-treated Raw264.7 macrophages. The in vivo study 
demonstrated that the administration of 1 mg/kg of neorogioltriol resulted in the significant 
reduction of carregeenan-induced rat edema. In vitro, our results show that neorogioltriol 
treatment  decreased  the  luciferase  activity  in  LPS-stimulated  Raw264.7  cells,  stably 
transfected with the NF-κB-dependent luciferase reporter. This effect on NF-κB activation 
is  not  mediated  through  MAPK  pathways.  The  inhibition  of  NF-κB  activity  correlates  
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with  decreased  levels  of  LPS-induced  tumor  necrosis  factor-alpha  (TNFα)  present  in 
neorogioltriol treated supernatant cell culture. Further analyses indicated that this product 
also  significantly  inhibited  the  release  of  nitric  oxide  and  the  expression  of 
cyclooxygenase-2 (COX-2) in LPS-stimulated Raw264.7 cells. These latter effects could 
only be observed for neorogioltriol concentrations below 62.5 µM. To our knowledge, this 
is  the  first  report  describing  a  molecule  derived  from  Laurencia  glandulifera  with  
anti-inflammatory activity both in vivo and in vitro. The effect demonstrated in vitro may 
be explained by the inhibition of the LPS-induced NF-κB activation and TNFα production. 
NO release and COX-2 expression may reinforce this effect.  
Keywords:  anti-inflammatory;  neorogioltriol;  Laurencia;  TNFα;  NF-κB;  NO;  
COX-2; carrageenan 
 
1. Introduction 
Natural products derived from plants provide an interesting and promising source for isolating and 
developing therapeutic molecules to fight against various diseases, including inflammatory ones [1]. In 
this respect, different natural products derived from marine organisms have been reported to exhibit a 
broad spectrum of pharmacological activity, including anti-inflammatory effects [2,3]. 
During the process of inflammation, different cell types are recruited, including monocytes that 
differentiate  locally into  macrophages. This leads to  the regulated production of various  pro- and  
anti-inflammatory mediators including cytokines, such as TNFα, chemokines and inducible enzymes 
(COX-2 and iNOS) that play critical roles in controlling the inflammatory processes. The expression of 
most  of  these  proteins  is  controlled,  at  least  in  part,  through  the  activation  of  a  conserved  and 
ubiquitous transcription factor, NF-κB which plays a key role in inflammatory response. 
Several natural products with anti-inflammatory effects have been shown to target and modulate the 
NF-κB signaling pathway, including a number of terpenoids [4,5]. Molecules belonging to this family 
were  isolated  from  different  marine  organisms  including  coral,  sponge  and  algae  [3].  Algae, 
particularly red algae, represent a rich source of different secondary metabolites, the majority of which 
consists  of  acetogenins,  halogenated  diterpenes  and  sesquiterpenes  [6–8].  Several  molecules  were 
derived  from  the  genus  Laurencia  and  have  been  shown  to  exhibit  a  number  of  different  
activities [9–11]. Using total extracts obtained from different algae, numerous studies have shown 
associated anti-inflammatory effects both in vivo [12,13] and in vitro [14,15]. However, to the best of 
our knowledge, purified molecules with anti-inflammatory effects have not yet been documented from 
the genus Laurencia. 
Recently, we have isolated neorogioltriol, a new diterpene with analgesic activity [16] from the 
organic  extract  of  the  red  algae  Laurencia  glandulifera.  In  this  report  we  investigated  the  
anti-inflammatory  activity  of  this  molecule  both  in  vivo,  experimenting  on  carrageenan-induced 
inflammation in the rat paw and in vitro, based on the expression of NF-κB and COX-2, as well as the 
release of TNFα and NO, from LPS-stimulated Raw264.7 macrophages. Mar. Drugs 2011, 9  
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2. Results and Discussion 
2.1. Effect of Neorogioltriol on Carrageenan-Induced Paw Edema in Rats 
The carrageenan-induced paw edema model in rats, one of the well-established acute inflammatory 
models in vivo, was used to test the anti-inflammatory activity of neorogioltriol. In the control group, 
the intraplantar injection of 100 µL of carrageenan (0.6%) into the rat’s hind paw induced a significant 
increase in paw edema (Table 1). This observation indicates the development of an inflammatory 
response and paw swelling (edema). The edema was present as early as one hour after carrageenan 
injection, progressed rapidly and persisted for at least 5 h after treatment. Both dexamethasone and 
ASA, used as positives controls, inhibited the oedematogenic response evoked by carrageenan in rats 
at  all  assessment  times.  However,  as  previously  reported  [17],  the  kinetics  of  the  effect  of  both 
components was different: whereas the dexamethasone-associated effect was rapid and produced a 
42% reduction of the edema after the first hour, the ASA-induced effect was slower (only 17% in the 
first hour), but reached a 59% inhibition by the fifth hour. Treatment of rats with the neorogioltriol 
molecule at an intraperitoneal dose of 1 mg/kg significantly reduced paw swelling at all time points 
tested (Table 1). This reduction was about 28% after the first hour and reached a maximum of 58% at 
3 h post injection. Moreover, a 1 mg/kg dose of neorogioltriol proved as effective as 300 mg/kg of 
ASA in reducing inflammation. 
Using  the  carrageenan-induced  paw  edema  model  in  rats,  our  results  showed  that  the  red  
algae-derived  natural  molecule  neorogioltriol  was  able  to  reduce  the  formation  of  edema  in  a 
concentration- and time-dependent manner.  
Table 1. Effect of neorogioltriol on carrageenan-induced paw edema in rats. 
Times after carageenan injection (h)  1 h  3 h  5 h 
Groups  Treatment  n 
Dose 
(mg/kg) 
EV  EI  EV  EI  EV  EI 
(10
−2 mL)  (%)  (10
−2 mL)  (%)  (10
−2 mL)  (%) 
Control  Control  6  -  18.3 ±  2.7  -  56.3 ±  5.8  -  69 ±  7.7  - 
Tests  Neorogioltriol 
6  0.5  15.5 ±  3.1  15.3  42 ±  5.5 (*)  33.3  49.1 ±  6.1  28.8 
1  14.1 ±  3 (*)  22.95  23.5 ±  3.7 (***)  58  33 ±  3.5 (**)  52.27 
References 
Aspirin (ASA)  6  300  16.5 ±  3.1  9.83  25.1 ±  6.7 (**)  55.17  28.1 ±  2.2 (**)  59.27 
Dexamethasone  6  1  9.83 ±  1.8  47.54  39.3 ±  3.8 (***)  42.5  32.5 ±  5.7 (***)  52.86 
Neorogioltriol (0.5 or 1 mg/kg) was administrated one hour before the intraplantar carrageenan injection. 
Reference  animals  were  treated  with  dexamethasone  (1  mg/kg)  or  aspirin  (ASA)  (300  mg/kg);  control 
animals received vehicle (0.9% NaCl) used to re-suspend the different drugs. Six animals were used for each 
treatment group. The drugs were administrated by intraperitoneal injection. The edema volume (EV) was 
determined immediately before and 1, 3, and 5 h after the carrageenan injection. When needed, the edema 
inhibition (EI) was calculated. The percentage of inhibition in treated rats versus control was calculated using 
the following formula: EI (%) = ([(Ct − C0) control − (Ct − C0) treated]/(Ct − C0) control) ×  100 where  
Ct  correspond  to  edema  volume  after  carrageenan  injection  and  C0  correspond  to  edema  volume  before 
carrageenan injection. The values are expressed as the mean ±  SD; * p < 0.05; ** p < 0.01; *** p < 0.001 
determined by Student’s t test compared with control. Mar. Drugs 2011, 9  
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2.2. Cell Viability 
Cytotoxic potential of neorogioltriol on Raw264.7 cells was tested using the MTT assay. Our result 
shows that in the presence of up to 250 µM of neorogioltriol, Raw264.7 macrophages viability was not 
significantly lower than in non-treated cells. We find cytotoxicity only at the highest neorogioltriol 
concentration (500 µM) which causes an optical density (OD) reduction of about 50%. 
Figure 1. Raw264.7 macrophages were either left untreated or were treated with various 
concentrations of neorogioltriol.  The  cytotoxic effects  were recorded at an observation 
period  of  24  h  by  using  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl  tetrazolium  bromide 
(MTT) test as described under “Experimental Section”. The cell number in each well was 
recorded in the form of optical density (OD). Data are expressed as means ±  SD of three 
independent experiments performed in triplicates. Results were analyzed by using one-way 
analysis of variance (ANOVA) with significance of p < 0.05. 
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2.3.  Effect  of  Neorogioltriol  on  TNFα  Release,  NO  Production  and  COX-2  Expression  in  
LPS-Stimulated Raw264.7 Cells 
Carrageenan-induced rat paw edema has been fully characterized and shown to be associated with 
the production of several inflammatory mediators [18,19] including TNFα, prostaglandins and nitric 
oxide release [20–22]. 
We first analyzed the effects of neorogioltriol in vitro, on different inflammatory molecules starting 
with  TNFα.  The  release  of  TNFα  was  measured  using  ELISA  assay  in  the  supernatant  of  
LPS-stimulated Raw264.7 cells, pre-treated or not with neorogioltriol for 30 min. The treatment of 
resting Raw264.7 cells with LPS increased the production of TNFα. For all the concentrations tested, 
neorogioltriol significantly inhibited TNFα production (Figure 2). Mar. Drugs 2011, 9  
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Figure 2. Effects of neorogioltriol on lipopolysaccharide (LPS)-induced tumor necrosis 
factor-alpha  (TNFα)  production  in  Raw264.7  cells.  Cells  were  treated  with  different 
concentrations ranging from 0.125 µM to 62.5 μM of neorogioltriol for 30 min prior to 
LPS (100 ng/mL) stimulation. Supernatants were collected 24 h later and cytokine content 
was  measured  by  ELISA.  Results  are  expressed  as  mean  values  of  three  independent 
experiments performed in duplicates, ± standard deviation. Statistically significant differences 
(p < 0.003) between all groups are verified by the Kruskal-Wallis non-parametric test. 
 
Cyclooxygenase-2 (COX-2) is the key  enzyme regulating  the production of prostaglandins, the 
central mediators of inflammation. On the other hand, iNOS activation induces massive NO production 
at the site of inflammation. We thus investigated the effect of our molecule on LPS-induced COX-2 
expression by Western blot and on NO production by measuring the released nitrite in the culture 
medium by Griess reaction. 
Our results show that in murine Raw264.7 cells, LPS treatment (100 ng/mL for 24 h) induces the 
expression of COX-2 (Figure 3A) and increases NO production 30-fold, as compared to controls. After 
neorogioltriol pretreatment, the LPS-induced nitrite release was inhibited. At concentrations ranging 
from 0.125 µM to 12.5 µM, neorogioltriol significantly reduced the level of NO production. However, 
for neorogioltriol concentrations above 25 µM the curve of NO release turns upward and at 62.5 µM 
(25 µg/mL) of neorogioltriol, NO release is almost similar to untreated cells (Figure 3A). 
The expression of COX-2 was also tested in cells treated with 12.5 µM, 25 µM and 62.5 µM 
neorogioltriol prior to LPS stimulation. Consistent with the inhibitory effect on NO release, the results 
(Figure  3B)  show  that  neorogioltriol  up  to  25  µM  inhibited  the  LPS  induced  COX-2  expression. 
However, at 62.5 µM the COX-2 expression is partially restored. 
Taken together, our data show that, whereas neorogioltriol has no effect by itself (data not shown), 
this molecule inhibits the expression of TNFα and COX-2 and the production of NO induced by  
LPS stimulated Raw264.7 cells. Neorogioltriol however, shows a biphasic effect since this molecule Mar. Drugs 2011, 9  
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fails  to  inhibit  the  expression  of  key  inflammatory  mediators,  such  as  COX-2  and  NO  at  the  
highest concentrations. 
Figure 3. (A) The effects of neorogioltriol on LPS-induced nitric oxide (NO) released in 
Raw264.7 cells. Cells were treated with different concentrations ranging from 0.125 µM to 
62.5 μM of neorogioltriol for 30 min and then LPS (100 ng/mL) was added. Supernatants 
were collected 24 h later and NO content was measured by ELISA. Results were mean 
values  of  three  independent  experiments,  performed  in  duplicates,  ± standard  deviation. 
Statistically  significant  differences  (p  <  0.038)  between  all  groups  are  verified  by  the 
Kruskal-Wallis  non-parametric  test;  (B)  The  effects  of  neorogioltriol  on  LPS-induced 
COX-2 expressions in Raw264.7 cells. Cells were treated with different concentrations 
(12.5 µM, 25 µM and 62.5 μM) of neorogioltriol for 30 min; then, LPS (100 ng/mL) was 
added  and  the  cells  were  incubated  for  24  h.  Total  cellular  proteins  were  resolved  by  
SDS-PAGE,  transferred  to  nitrocellulose  membranes,  and  detected  with  specific 
antibodies, as described in the Experimental Section. A representative immunoblot of three 
separate experiments is shown.  
(A) 
 
(B) 
NS                0             12. 5             25             62.5       Neorogiotriol (µ M)
+                +                +              +            LPS (100 ng/ml) (24h)
COX-2
ERK1/2-T
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2.4. Effects of Neorogioltriol on NF-κB Transactivation in LPS-Stimulated Raw264.7 Cells 
The anti-inflammatory potential of terpenes has been linked to their capacity to suppress NF-κB 
signaling  [4,23]  which  coordinates  the  expression  of  proinflammatory  enzymes  and  cytokines 
including iNOS, COX-2 and TNFα [24–26]. Neorogioltriol was thus evaluated in vitro for its ability to 
inhibit  LPS-mediated  NF-κB  transcriptional  activity.  Raw264.7  cells,  stably  transfected  with  
pNF-κB-luc  plasmid,  containing  three  NF-κB  target  sequences  linked  upstream  to  the  luciferase 
reporter  gene,  were  either  stimulated  with  LPS  or  treated  with  different  concentrations  of 
neorogioltriol prior to LPS stimulation. Our result shows that LPS induces NF-κB activation. The  
pre-treatment with neorogioltriol prior to LPS stimulation significantly decreased LPS induced NF-κB 
transactivation  (Figure  4).  This  result  shows  that  the  anti-oedematogenic  effect  of  neorogioltriol 
correlates with the suppression of NF-κB activation. 
However, despite reducing NF-κB activity, high concentrations of neorogioltriol fail to inhibit the 
expression of certain NF-κB-dependent genes that are relevant to the inflammatory process, such as 
COX-2. These results suggest that the observed loss of anti-inflammatory efficacy at high doses of 
neorogioltriol was independent of NF-κB or indirectly dependent on NF-κB inhibition.  
Figure  4.  The  inhibition  of  NF-κB  activation  by  neorogioltriol.  Cells  were  stably 
transfected with a pNF-κB-Luc reporter and then were pretreated for 30 min with different 
concentrations (12.5 µM, 25 µM and 62.5 μM) of neorogioltriol. LPS (100 ng/mL) was 
then added and the cells were further incubated for 6 hours. The cells were harvested and 
luciferase activities were determined in cell lysates and normalized to protein content using 
a luminometer TD-20/20 (Promega, charbonnieres, France). Results are representative of 
three different experiments and are expressed as the fold increase in luciferase activity 
induced by the specific experimental condition, relative to the luciferase activity measured 
in LPS stimulated cells. Statistically significant differences (p < 0.01) between all groups 
are verified by the Kruskal-Wallis non-parametric test.  
 Mar. Drugs 2011, 9  
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2.5. Effect of Neorogioltriol on MAPK in LPS-Stimulated Raw264.7 Cells 
The mitogen-activated protein (MAP) kinases play a key role in the regulation of cellular response 
to cytokines and stresses and are also known to be important for NF-κB activation. We thus tested 
whether the observed loss of anti-inflammatory efficacy may be mediated through MAPK activation. 
We first studied the effect of neorogioltriol on LPS-induced MAPK activation. Our results show 
that at the highest concentrations used (25 µM  and 62.5 µM), the neorogioltriol molecule fails to 
interfere  with  LPS-dependent  ERK  activation  and  only  slightly  inhibited  the  p38  MAPK 
phosphorylation (Figure 5). Moreover, the inhibition of MAPK pathways by PD98059 or SB203580 
treatment did not alter the capacity of neorogioltriol to inhibit the LPS-induced NF-κB transactivation 
(data not shown). 
Figure 5. Effect of neorogioltriol on MAPK activation in LPS-stimulated Raw264.7 cells. 
Cells  were  pretreated  for  30  min  with  62.5  μM  (or  25  μM)  of  neorogioltriol.  LPS  
(100 ng/mL) was then added and the cells were further incubated for indicated times. Cells 
were collected and subjected to Western blotting with antibodies specific for phosphorylated 
forms of p38 (p38MAPK-P) or ERK1/2 (ERK1/2-P). Total ERK immunoblots were shown 
as loading control; similar results were obtained for the two concentrations of neorogioltriol 
used. Results are representative of two independent experiments. 
 
MAPKs  have  been  reported  to  be  involved  in  the  LPS-induced  iNOS  expression  signaling  
pathway [27] which regulates the production of NO which, in turn, may enhance the expression of 
COX-2.  On  the  other  hand,  at  the  highest  concentrations  used,  neorogioltriol  does  not  display  a Mar. Drugs 2011, 9  
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significant inhibitory effect on MAPK phosphorylation. Using SB203580 (or PD98059), we thus tried 
to see whether or not MAPK activity may explain the recovery of NO release by the cells treated with 
the highest concentrations of neorogioltriol. 
Raw264.7 cells were incubated for one hour with SB203580 (or PD98059) prior to neorogioltriol 
treatment and LPS stimulation. Our results show that the use of p38MAPK (or ERK1/2) inhibitor does 
not inhibit the recovery of NO production observed with the highest concentration of neorogioltriol 
(Figure  6)  suggesting  that  abrogation  of  NO  inhibition  in  the  neorogioltriol  treated  cells  is  not 
dependent on MAPK activation. 
Figure 6. Effect of p38 MAPK inhibitor on NO release in neorogioltriol treated Raw264.7 
cells.  Cells  were  pretreated  for  one  hour  with  SB203580  (10  μM)  and  then  with 
neorogioltriol (12.5 μM, 25 μM or 62.5 μM) before LPS stimulation. Supernatants were 
collected 24 h later and NO content measured by Griess reagent. Results were mean values 
of two independent experiments, performed in duplicate, ± standard deviation. Comparisons 
between  SB203580  treated  and  non  treated  cells  were  made  using  the  non-parametric 
Mann-Whitney test, with significance of p < 0.05. 
 
Taken  together,  these  results  show  that  the  effect  of  neorogioltriol  at  high  concentration  is 
independent  of  MAPK  and  NF-κB.  This  effect  may  however  be  indirectly  dependent  on  NF-κB 
inhibition. Indeed, some non steroid anti-inflammatory drugs (NSAIDs) are known to activate COX-2 
through  signaling  pathways  independent  of  NF-κB  and  MAPK  and  involving  the  nuclear  factor 
PPARγ.  On  the  other  hand,  LPS  has  been  shown  to  drive  down  PPARγ  expression  through  the 
activation of NF-κB [28]. This may suggest that the repression of NF-κB by neorogioltriol inhibits the 
negative loop of NF-κB on PPARγ, which may allow the latter to induce the expression of NOS2 and 
COX-2. We are currently investigating this hypothesis. Mar. Drugs 2011, 9  
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3. Experimental Section 
3.1. Isolation of Neorogioltriol 
The  collection  of  Laurencia  glandulifera  and  the  extraction  and  isolation  procedure  of 
neorogioltriol have been already described [16]. 
3.2. Carrageenan-Induced Paw Edema 
The anti inflammatory activity on carrageenan-induced paw edema was determined according to the 
method described by [29]. Naï ve rats were randomly allocated to four groups and pretreated 1 hour 
before  intraplantar  administration  of  100  μL  of  0.6%  of  carrageenan.  (i)  Control  group:  received  
2.5 mL/kg of vehicle (physiological solution (0.9% NaCl)) used to re-suspend the different drugs  
(ii)  Standard  group  1:  received  1  mg/kg  of  dexamethasone  (2.5  mL/kg);  (iii)  Standard  group  2: 
received 300 mg/kg of asprin (2.5 mL/kg); and (iiii) Test group: received 1 mg/kg or 0.5 mg/kg of 
neorogioltriol  (2.5  mL/kg).  The  drugs  were  administrated  by  intraperitoneal  injection.  The  edema 
volume was determined using a plethysmometer (model 7150, Ugo Basile, Italy) prior to and 1, 3 and 
5  h  after  carrageenan  injection.  The  percentage  of  inhibition  in  treated  rats  versus  control  was 
calculated using the following formula: EI (%) = ([(Ct − C0) control − (Ct − C0) treated]/(Ct − C0) 
control) ×  100 where Ct correspond to edema volume after carrageenan injection and C0 correspond to 
edema volume before carrageenan injection. 
3.3. Reagents and Antibodies 
ERK1/2  antibodies  and  p38  MAPK  antibodies  were  from  Ozyme  (Ozyme,  Saint  Quentin  en 
Yveline, France). COX-2 antibody was from Becton Dickinson (BD Biosciences, France). PD098059, 
SB203580, LPS and griess reagent were purchased from Sigma (Sigma-Aldrich, Taufkirchen, Germany). 
3.4. Cells Culture 
The  mouse  macrophagic  cell  line  Raw264.7  cells  were  obtained  from  American  Type  Culture 
Collection and were grown at 37 ° C, in RPMI 1640, supplemented with 5 mM L-glutamine, 10% heat 
inactivated  fetal  calf  serum  (endotoxin-free;  HyClone),  penicillin  (100  U/mL)  and  streptomycin  
(100 µg/mL). 
3.5. Cytotoxicity Test 
The  MTT  assay  was  used  to  test  the  potential  toxic  effects  of  neorogioltriol  on  the  mouse 
macrophagic  cell  line  Raw264.7  cells.  Briefly,  Raw264.7  cells  were  incubated  with  various 
concentrations  of  neorogioltriol  for  24  h.  MTT  solution  was  added  to  cell  cultures  at  the  final 
concentration of 0.5 mg/mL and cells were incubated for an additional 2 h. Thereafter, medium was 
removed  and  plates  were  thoroughly  washed  with  PBS.  Cells  were  finally  lysed  in  DMSO.  The 
absorbance of each well at 540 nm was read by an automatic microplate reader. The average OD 
measured  at  different  concentrations  of  neorogioltriol  was  compared  using  one-way  analysis  of Mar. Drugs 2011, 9  
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variance (ANOVA). Proliferation of the cells exposed to the drugs was compared to the negative 
control. P < 0.05 was considered statistically significant. 
3.6. Transfection and Luciferase Assay 
Raw264.7  cells  were  stably  transfected  by  electroporation  with  an  NF-κB  luciferase  reporter 
construct containing three NF-κB target sequences in tandem fused to the luciferase reporter gene  
(3X-NF-κB-Luc), a gift from Dr J. Pierre (Faculté  de pharmacy, Chatenay-Malabry, France). Cells 
were either left untreated or were treated with neorogioltriol at different doses for 30 min, they were 
then washed and stimulated with LPS (100 ng/mL) for an additional 6 hours. Protein concentration 
was determined by microBCA assay. Luciferase activity was determined using a luminometer TD-20/20 
(Promega, charbonnieres, France). 
3.7. Western Blot Analysis 
Cell extracts were obtained by adding 25 µL of lysis buffer containing 10 mM Tris-HCL, pH 7.5, 
50  mM  NaCl,  50  mM  sodium  fluoride  (NaF),  2  mM  EDTA,  1  mM  ethylene  glycol-bis  
(β-aminoethylether)-N,N,N′,N′-tetraacetic  acid  (EGTA),  2%  Nonidet-P40  (NP-40),  0.75%  sodium 
deoxycholate (DOC), 1 mM orthovanadate, 1 µg/mL aprotinine, 1 mM PMSF, 1 mM DTT. After  
30 min incubation on ice, the extracts were centrifuged at 15,000 rpm for 20 min. 25 µg of whole cell 
lysates were resolved by electrophoresis in a 12% SDS-polyacrylamide gel. Resolved proteins were 
electrophoretically  transferred  onto  PVDF  sheets  (Hybond-P;  Amersham)  and  membranes  were 
blocked by incubation in 3% non-fat milk and  0.1% Tween in PBS for 1 h at room temperature 
followed by incubation with COX-2 antibody in 0.1% Tween-PBS. Bound antibody was detected by 
incubation with horseradish peroxidase-coupled secondary antibody (Amersham Pharmacia Biotech., 
Buckinghamshire, UK). To ensure equal loading, the blots were then stripped (62.5 mM Tris, pH 6.8), 
0.1 M β-mercaptoethanol, 2% SDS) and re-probed with ERK1/2 antibody. 
3.8. Measurements of Nitrite Production and Cytokine Assays 
Macrophage cells were seeded in 24 wells, treated with different concentrations of neorogioltriol or 
vehicle for 30 min and then incubated with 100 ng/mL of LPS for 24 h. NO production in culture 
supernatant was spectrophotometrically evaluated by measuring nitrite, an oxidative product of NO. 
Nitrites were measured by Griess reaction by mixing 50 µL of culture supernatant with 50 µL of  
griess  reagent.  Absorbance  was  measured  in  microplates  at  540  nm  against  a  calibration  curve  
with  sodium  nitrite  standard.  Supernatants  were  also  analysed  for  TNFα  content  using  BD  
Pharmingen  (BD  Biosciences,  France)  antibodies.  The  assays  were  performed  according  to  the  
manufacturer’s instructions. 
3.9. Statistical Analysis 
For  TNFα  production,  NO  release  and  NF-κB  activation,  the  Kruskal-Wallis  test  was  used  to 
analyze significant differences between groups. The comparison between the two groups (presence or Mar. Drugs 2011, 9  
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absence of SB203580) was performed using the Mann-Whitney test. For all statistical comparisons a  
p value <0.05 was defined as significant. 
4. Conclusions 
As far as could be ascertained, this is the first report that shows anti-inflammatory activity for a 
purified  algal  metabolite.  We  have  demonstrated  that,  in  addition  to  its  analgesic  activity  [16], 
neorogioltriol exhibits anti-inflammatory activity in vivo. This effect may be explained by the capacity 
of neorogioltriol, at all concentrations tested, to inhibit NF-κB transactivation and TNFα release. The 
inhibitory effect of this compound on COX-2 expression and NO release is likely to reinforce the  
anti-inflammatory  effect  of  neorogioltriol  at  concentrations  below  62.5  µM.  However,  the  exact 
mechanism of neorogioltriol action needs to be clarified and the target molecule in the cell identified.  
Acknowledgements 
This work was supported by the Ministry for High Education and Scientific Research (Tunisia). The 
authors wish to acknowledge N. Bahi-Jabber for assistance with the statistical analysis. 
References  
1.  Balunas,  M.J.;  Kinghorn,  A.D.  Drug  discovery  from  medicinal  plants.  Life  Sci.  2005,  78,  
431–441. 
2.  Jha,  R.K.;  Zi-rong,  X.  Biomedical  compounds  from  Marine  organisms.  Mar.  Drugs  2004,  
2, 123–146. 
3.  Mayer, A.M.; Rodriguez, A.D.; Berlinck, R.G.; Hamann, M.T. Marine pharmacology in 2005–6: 
Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, 
antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, 
immune and nervous systems, and other miscellaneous mechanisms of action. Biochim. Biophys. 
Acta 2009, 1790, 283–308. 
4.  Salminen, A.; Lehtonen, M.; Suuronen, T.; Kaarniranta, K.; Huuskonen, J. Terpenoids: natural 
inhibitors of NF-κB signaling with anti-inflammatory and anticancer potential. Cell Mol. Life Sci. 
2008, 65, 2979–2999. 
5.  Folmer, F.; Jaspars, M.; Dicato, M.; Diederich, M. Marine natural products as targeted modulators 
of the transcription factor NF-κB. Biochem. Pharmacol. 2008, 75, 603–617. 
6.  Konig, G.M.; Wright, A.D. Sesquiterpene content of the antibacterial dichloromethane extract of 
the marine red alga Laurencia obtusa. Planta Med. 1997, 63, 186–187. 
7.  Iliopoulou,  D.;  Mihopoulos,  N.;  Vagias,  C.;  Papazafiri,  P.;  Roussis,  V.  Novel  cytotoxic 
brominated diterpenes from the red alga Laurencia obtusa. J. Org. Chem. 2003, 68, 7667–7674. 
8.  Kladi, M.; Vagias, C.; Stavri, M.; Rahman, M.M.; Gibbons, S.; Roussis, V. C15 acetogenins with 
antistaphylococcal activity from the red alga Laurencia glandulifera. Phytochem. Lett. 2008, 1, 
31–36. 
9.  El Sayed, K.A.; Dunbar, D.C.; Perry, T.L.; Wilkins, S.P.; Hamann, M.T.; Greenplate, J.T. Marine 
natural products as prototype insecticidal agents. J. Agric. Food Chem. 1997, 45, 2735–2739. Mar. Drugs 2011, 9  
 
 
1305 
10.  Vairappan, C.S. Potent antibacterial activity of halogenated metabolites from Malaysian red algae, 
Laurencia majuscula (Rhodomelaceae, Ceramiales). Biomol. Eng. 2003, 20, 255–259. 
11.  Jung, W.K.; Choi, I.; Oh, S.; Park, S.G.; Seo, S.K.; Lee, S.W.; Lee, D.S.; Heo, S.J.; Jeon, Y.J.;  
Je, J.Y.; et al. Anti-asthmatic effect of marine red alga (Laurencia undulata) polyphenolic extracts 
in a murine model of asthma. Food Chem. Toxicol. 2009, 47, 293–297. 
12.  Guzman,  S.;  Gato,  A.;  Calleja, J.M. Antiinflammatory, analgesic  and  free radical scavenging 
activities  of  the  marine  microalgae  Chlorella  stigmatophora  and  Phaeodactylum  tricornutum. 
Phytother. Res. 2001, 15, 224–230. 
13.  Dar,  A.;  Baig,  H.S.;  Saifullah,  S.M.;  Ahmad,  V.U.;  Yasmeen,  S.;  Nizamuddin,  M.  Effect  of 
seasonal  variation  on  the  anti-inflammatory  activity  of  Sargassum  wightii  growing  on  the  N. 
Arabian Sea coast of Pakistan. J. Exp. Mar. Biol. Ecol. 2007, 351, 1–9. 
14.  Jin, D.Q.; Lim, C.S.; Sung, J.Y.; Choi, H.G.; Ha, I.; Han, J.S. Ulva conglobata, a marine algae, 
has neuroprotective and anti-inflammatory effects in murine hippocampal and microglial cells. 
Neurosci. Lett. 2006, 402, 154–158. 
15.  Yoon,  W.J.;  Ham,  Y.M.;  Kim,  K.N.;  Park,  S.Y.;  Lee,  N.H.;  Hyun,  C.G.;  Lee,  W.J.  
Anti-inflammatory activity of brown alga Dictyota dichotoma in murine macrophage Raw264.7. 
J. Med. Plants Res. 2009, 3, 1–8. 
16.  Chatter,  R.;  Kladi,  M.;  Tarhouni,  S.;  Maatoug,  R.;  Kharrat,  R.;  Vagias,  C.;  Roussis,  V. 
Neorogioltriol:  A  brominated  diterpene  with  analgesic  activity  from  Laurencia  glandulifera. 
Phytochem. Lett. 2009, 2, 25–28. 
17.  Holsapple,  M.P.;  Schnur,  M.;  Yim,  G.K.  Pharmacological  modulation  of  edema  mediated  by 
prostaglandin, serotonin and histamine. Agents Actions 1980, 10, 368–373. 
18.  Di Rosa, M.; Giroud, J.P.; Willoughby, D.A. Studies of the acute inflammatory response induced 
in rat in different sites by carrageenan and turpentine. J. Pathol. 1971, 104, 15–29. 
19.  Garcia Leme, J.; Hamamura, L.; Leite, M.P.; Rocha e Silva, M. Pharmacological analysis of the 
acute inflammatory process induced in the rat’s paw by local injection of carrageenin and by 
heating. Br. J. Pharmacol. 1973, 48, 88–96. 
20.  Cunha, F.Q.; Poole, S.; Lorenzetti, B.B.; Ferreira, S.H. The pivotal role of tumour necrosis factor 
alpha in the development of inflammatory hyperalgesia. Br. J. Pharmacol. 1992, 107, 660–664. 
21.  Salvemini,  D.;  Wang,  Z.Q.;  Wyatt,  P.S.;  Bourdon,  D.M.;  Marino,  M.H.;  Manning,  P.T.;  
Currie, M.G. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat 
paw inflammation. Br. J. Pharmacol. 1996, 118, 829–838. 
22.  Omote, K.; Hazama, K.; Kawamata, T.; Kawamata, M.; Nakayaka, Y.; Toriyabe, M.; Namiki, A. 
Peripheral nitric oxide in carrageenan-induced inflammation. Brain Res. 2001, 912, 171–175. 
23.  de las Heras, B.; Hortelano, S. Molecular basis of the anti-inflammatory effects of terpenoids. 
Inflamm. Allergy Drug Targets 2009, 8, 28–39. 
24.  Xie, Q.W.; Kashiwabara, Y.; Nathan, C. Role of transcription factor NF-κB/Rel in induction of 
nitric oxide synthase. J. Biol. Chem. 1994, 269, 4705–4708. 
25.  Chen, F.; Kuhn, D.C.; Sun, S.C.; Gaydos, L.J.; Demers, L.M. Dependence and reversal of nitric 
oxide  production  on  NF-κB  in  silica  and  lipopolysaccharide-induced  macrophages.  Biochem. 
Biophys. Res. Commun. 1995, 214, 839–846. Mar. Drugs 2011, 9  
 
 
1306 
26.  Schmedtje,  J.F.,  Jr.;  Ji,  Y.S.;  Liu,  W.L.;  DuBois,  R.N.;  Runge,  M.S.  Hypoxia  induces 
cyclooxygenase-2 via the NF-κB p65 transcription factor in human vascular endothelial cells.  
J. Biol. Chem. 1997, 272, 601–608. 
27.  Chen, C.C.; Wang, J.K. p38 but not p44/42 mitogen-activated protein kinase is required for nitric 
oxide  synthase  induction  mediated  by  lipopolysaccharide  in  Raw264.7  macrophages.  
Mol. Pharmacol. 1999, 55, 481–488. 
28.  Necela,  B.M.;  Su,  W.;  Thompson,  E.A.  Toll-like  receptor  4  mediates  cross-talk  between 
peroxisome  proliferator-activated  receptor  gamma  and  nuclear  factor-κB  in  macrophages. 
Immunology 2008, 125, 344–358. 
29.  Winter, C.A.; Risley, E.A.; Nuss, G.W. Carrageenin-induced edema in hind paw of the rat as 
assay for anti-inflammatory drug. Proc. Soc. Exp. Biol. Med. 1962, 111, 544–547. 
Samples Availability: Available from the authors. 
© 2011  by the authors;  licensee  MDPI,  Basel, Switzerland. This  article is an open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 